Effect of irradiation and operation on serum lactic dehydrogenase and glutamic oxalacetic transaminase in patients with malignant tumors

OUP accepted manuscript

Circulating biomarkers have emerged as valuable surrogates for evaluating disease states in solid malignancies. Their relative ease of access and rapid turnover has bolstered clinical applications in monitoring treatment efficacy and cancer progression. In this review, the roles of various circulating biomarkers in monitoring treatment response are described. Non-specific markers of disease burden, tumor markers (eg CA 125, CEA, PSA, etc.), circulating tumor cells, nucleic acids, exosomes, and metabolomic arrays are highlighted. Specifically, the discovery of each of these markers is reviewed, with examples illustrating their use in influencing treatment decisions, and barriers to their application noted where these exist. Finally, opportunities for future work using these circulating biomarkers are discussed.

Clinical enzymology in cancer

It is fair to say that so far, and with few exceptions, the application of enzymology to clinical oncology has been disappointing. This is certainly true with regard to cancer screening and diagnosis. It is unlikely that any single enzyme or isoenzyme will emerge as a sufficiently sensitive or specific indicator of cancer, and it would seem more profitable to focus on multivariate or pattern analysis of several enzymes and other measurable body fluid constituents. Another suggested approach would be to establish the normal enzyme levels for individuals and then follow them for changes which might signal the development of a neoplasm. Finally, Weber's concept of key enzymes as the phenotypic markers of neoplasia and targets of chemotherapy would appear to open a new avenue for enzymology in clinical oncology.